# Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

> **NCT02573272** · — · UNKNOWN · sponsor: **Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud** · enrollment: 204 (estimated)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** eslicarbacepine

## Key facts

- **NCT ID:** NCT02573272
- **Lead sponsor:** Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2016-07
- **Final completion:** 2016-10
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573272, "Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02573272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*